magazine 1 Apr 2021
Download PDF Page flip version
ESG investments are all the rage but sometimes they’re not what they appear to be. The latest edition of Shares looks at the issue of greenwashing and how to distinguish the fakers from those really doing good.
The digital magazine also includes details of Deliveroo’s big IPO flop, examines online used car marketplace Cazoo’s US listing plans and discusses some last minute ISA ideas as the end of the tax year approaches.
Find out about Boohoo’s attempts to address the scandals in its supply chain, what’s different about new computer games stock tinyBuild and how someone drawn into investing by GameStop mania might come up with a sensible investment plan.
China equity funds hit as stocks undergo a correction on mounting risk
London’s quoted used car dealerships will be watching Cazoo’s move with interest
Early investors face large paper losses as institutions shun UK’s biggest IPO in a decade
Providing explicit commentary in this area would be a step in the right direction
Sustainable investments are all the rage but sometimes they are not what they appear to be
We look for companies that score well on quality metrics and where analysts have been upgrading earnings forecasts
Playing the momentum game for short-term gains
The online fashion seller is repairing its tattered reputation which means disgruntled investors might want to give it another look
30-year-old Joe has been drawn in by GameStop mania but wants to take a sensible approach to the markets
Developing video games into multi-media franchises with multiple revenue streams is the company’s mantra
History suggests getting started at the beginning of the tax year is better than waiting until the end of it
The newspaper publisher benefits from investment in an early-stage business
Low-cost deposit base gives it the scope to find winning investments
Software reseller could easily surprise on the upside again to power stock over £20
Chief executive has the skills to keep improving the brand
The company is one of just a few firms globally providing a key material for mRNA treatments like vaccines, which could provide big returns
The wider implications as a US hedge fund turns forced seller of stocks
A reader asks why 47 years’ worth of National Insurance contributions isn’t enough to get the full rate
Important information:
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
